SCHEMBL5699210

SCHEMBL5699210

O=[N+]([O-])c1cccc(Br)c1OC(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.41
HSPB1 P04792 1/20 0.41
GPR35 Q9HC97 2/20 0.40
NPC1 O15118 1/20 0.39
RECQL P46063 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 6/20 0.37
TSHR P16473 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
S100A4 P26447 2/20 0.37
PTPRC P08575 1/20 0.37
CYP1A2 P05177 3/20 0.36
MAPT P10636 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
MAPK1 P28482 2/20 0.36
CYP2C19 P33261 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29134271 0.87 HSPB1 (0.39) TDP1HSPB1GPR35NPC1RECQL
SCHEMBL15283229 0.83 TDP1 (0.44) TDP1HSPB1GPR35NPC1RECQL
SCHEMBL26162786 0.80 TDP1 (0.39) TDP1HSPB1GPR35NPC1RECQL
SCHEMBL7124190 0.80 MAPT (0.47) TDP1HSPB1GPR35NPC1RECQL
SCHEMBL7125229 0.80 TDP1 (0.41) TDP1HSPB1GPR35NPC1RECQL
SCHEMBL28837910 0.78 CYP1A2 (0.43) TDP1GPR35NPC1RAB9AALDH1A1
SCHEMBL28837911 0.78 CYP1A2 (0.43) TDP1GPR35NPC1RAB9AALDH1A1
SCHEMBL1771083 0.78 MEN1 (0.36) MEN1ALOX15KMT2A
SCHEMBL31226691 0.78 ALDH1A1 (0.41) TDP1HSPB1GPR35NPC1RECQL
SCHEMBL30778343 0.78 ALDH1A1 (0.40) TDP1ALDH1A1TSHRMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637435-B2 Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof FUJIFILM CORPORATION (JP) 2026-05-26 US disclosed
US-12421217-B2 Pyrazine derivative or salt thereof, and use of same FUJIFILM CORPORATION (JP) 2025-09-23 US disclosed
EP-4190402-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORP (JP) 2025-08-27 EP disclosed
US-20250163004-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2025-05-22 US disclosed
US-20240190829-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2024-06-13 US disclosed
CN-117794912-A Substituted heterocyclic compounds 百时美施贵宝公司 2024-03-29 CN disclosed
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) 2024-03-28 US disclosed
EP-4337655-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS Bristol-Myers Squibb Company (US) 2024-03-20 EP disclosed
EP-4052760-B1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM CORP (JP) 2024-03-13 EP disclosed
US-11866414-B2 Substituted heterocyclic compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-09 US disclosed
US-20220259185-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM CORPORATION (JP) 2022-08-18 US disclosed
CN-114901656-A Hydroximic acid ester compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2022-08-12 CN disclosed
WO-2022117016-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳微芯生物科技股份有限公司 2022-06-09 WO disclosed
WO-2022025174-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF 富士フイルム株式会社 2022-02-03 WO disclosed
WO-2021085582-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME 富士フイルム株式会社 2021-05-06 WO disclosed
EP-1362843-B1 N-cyclopropyl-2-difluoromethoxy-3-bromoaniline and intermediate used for production thereof IHARA CHEMICAL IND CO (JP) 2006-06-14 EP disclosed
EP-1031555-B1 DIFLUOROMETHOXYBENZENE DERIVATIVES AND THEIR USE AS INTERMEDIATES IHARA CHEMICAL IND CO (JP) 2005-04-13 EP disclosed
EP-1362843-A2 N-cyclopropyl-2-difluoromethoxy-3-halogenoaniline and intermediate used for production thereof Ihara Chemical Industry Co., Ltd. (JP) 2003-11-19 EP disclosed
US-6316658-B1 QUINOLONE CARBOXYLATE CHEMICAL INTERMEDIATES; MICROBIOCIDES, BACTERICIDES IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2001-11-13 US disclosed
EP-1031555-A1 N-CYCLOPROPYL-2-DIFLUOROMETHOXY-3-HALOGENOANILINES AND INTERMEDIATES FOR THE PREPARATION THEREOF IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2000-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TYK2, WEE2, WEE1 TDP1 1205/4885HSPB1 2825/4885GPR35 1916/4885
US-11866414-B2 Substituted heterocyclic compounds TYK2, JAK2, STAT3 TDP1 455/4885HSPB1 4123/4885GPR35 994/4885
US-20250163004-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS TYK2, JAK2, STAT3 TDP1 455/4885HSPB1 4123/4885GPR35 994/4885
US-12421217-B2 Pyrazine derivative or salt thereof, and use of same DHODH, IDH1, IDH2 TDP1 1422/4885HSPB1 3161/4885GPR35 3104/4885
US-12637435-B2 Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof CBR1, DHODH, CBR3 TDP1 2604/4885HSPB1 3854/4885GPR35 3504/4885
US-20240190829-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS TYK2, JAK2, STAT3 TDP1 455/4885HSPB1 4123/4885GPR35 994/4885
US-20220259185-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME DHODH, IDH1, IDH2 TDP1 1422/4885HSPB1 3161/4885GPR35 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.